File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B

TitleHigh serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B
Authors
KeywordsCase-control studies
Cytokines
Fibrosis
Hepatitis B
Interleukin-6
Liver neoplasms
Issue Date2009
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2009, v. 124 n. 12, p. 2766-2770 How to Cite?
Abstract
Increased interleukin-6 (IL-6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL-6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case-control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty-seven patients developed HCC at a median follow-up of 62 months (interquartile range: 41-110). Serum IL-6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL-6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL-6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL-6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high-risk patients for HCC surveillance program. © 2009 UICC.
Persistent Identifierhttp://hdl.handle.net/10722/92203
ISSN
2013 Impact Factor: 5.007
ISI Accession Number ID
Funding AgencyGrant Number
Chinese University of Hong Kong2007.2.018
Research Fund of the Department of Medicine and Therapeutics
Funding Information:

Grant sponsors: The Chinese University of Hong Kong and the Research Fund of the Department of Medicine and Therapeutics, The Chinese University of Hong Kong; Grant number: 2007.2.018.

References

 

DC FieldValueLanguage
dc.contributor.authorWong, VWSen_HK
dc.contributor.authorYu, Jen_HK
dc.contributor.authorCheng, ASLen_HK
dc.contributor.authorWong, GLHen_HK
dc.contributor.authorChan, HYen_HK
dc.contributor.authorChu, ESHen_HK
dc.contributor.authorNg, EKOen_HK
dc.contributor.authorChan, FKLen_HK
dc.contributor.authorSung, JJYen_HK
dc.contributor.authorChan, HLYen_HK
dc.date.accessioned2010-09-17T10:39:07Z-
dc.date.available2010-09-17T10:39:07Z-
dc.date.issued2009en_HK
dc.identifier.citationInternational Journal Of Cancer, 2009, v. 124 n. 12, p. 2766-2770en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92203-
dc.description.abstractIncreased interleukin-6 (IL-6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL-6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case-control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty-seven patients developed HCC at a median follow-up of 62 months (interquartile range: 41-110). Serum IL-6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL-6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL-6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL-6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high-risk patients for HCC surveillance program. © 2009 UICC.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectCase-control studiesen_HK
dc.subjectCytokinesen_HK
dc.subjectFibrosisen_HK
dc.subjectHepatitis Ben_HK
dc.subjectInterleukin-6en_HK
dc.subjectLiver neoplasmsen_HK
dc.subject.meshCarcinoma, Hepatocellular - blood - virology-
dc.subject.meshHepatitis B virus - isolation and purification-
dc.subject.meshHepatitis B, Chronic - blood - virology-
dc.subject.meshInterleukin-6 - blood-
dc.subject.meshLiver Neoplasms - blood - virology-
dc.titleHigh serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0020-7136&volume=124&issue=12&spage=2766&epage=2770&date=2009&atitle=High+serum+interleukin-6+level+predicts+future+hepatocellular+carcinoma+development+in+patients+with+chronic+hepatitis+B-
dc.identifier.emailNg, EKO: ngko@hku.hken_HK
dc.identifier.authorityNg, EKO=rp01364en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ijc.24281en_HK
dc.identifier.pmid19267406en_HK
dc.identifier.scopuseid_2-s2.0-65649111667en_HK
dc.identifier.hkuros168711-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-65649111667&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume124en_HK
dc.identifier.issue12en_HK
dc.identifier.spage2766en_HK
dc.identifier.epage2770en_HK
dc.identifier.isiWOS:000265997500002-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, VWS=7202525502en_HK
dc.identifier.scopusauthoridYu, J=35351306800en_HK
dc.identifier.scopusauthoridCheng, ASL=7402075036en_HK
dc.identifier.scopusauthoridWong, GLH=9248570900en_HK
dc.identifier.scopusauthoridChan, HY=25821923600en_HK
dc.identifier.scopusauthoridChu, ESH=8631130300en_HK
dc.identifier.scopusauthoridNg, EKO=21135553700en_HK
dc.identifier.scopusauthoridChan, FKL=7202586434en_HK
dc.identifier.scopusauthoridSung, JJY=24473715000en_HK
dc.identifier.scopusauthoridChan, HLY=25722700100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats